GlassScriptPhysician profile
Pramila Daftary
NPI 1255399945
$2,558.04
in general payments reported to CMS, 2019-2025
20 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $1,043 · 2021: $179 · 2022: $262 · 2023: $361 · 2024: $301 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $781.35 | 2020 | |
| Glaxosmithkline, LLC. | $366.19 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $179.81 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $170.09 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $163.58 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $153.50 | 2019-2025 | Dupixent |
| Blueprint Medicines Corporation | $134.93 | 2023-2024 | Ayvakit |
| Genzyme Corporation | $133.15 | 2020-2024 | |
| Mylan Specialty L.P. | $123.22 | 2019-2022 | |
| Csl Behring | $65.44 | 2019-2025 | Hizentra |
| Amgen INC. | $58.16 | 2022-2025 | Tezspire |
| Hospira, INC. | $40.36 | 2024-2025 | |
| Kaleo, INC. | $33.96 | 2020 | |
| Alk-Abello, INC | $33.65 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $33.21 | 2021-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $28.64 | 2019 | |
| Aimmune Therapeutics, INC. | $24.13 | 2023 | |
| Lilly USA, LLC | $22.56 | 2024 | Ebglyss |
| Takeda Pharmaceuticals U.S.A., INC. | $12.11 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pramila Daftary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.